Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
Peer Reviewed
See detailLow macrolide resistance in Streptococcus pyogenes in Southern Argentina.
Rubinstein, Gabriela; Amoroso, Ana Maria ULg; Bavdaz, Barbara et al

in International journal of antimicrobial agents (2005), 25(5), 450-2

Detailed reference viewed: 12 (1 ULg)
Full Text
Peer Reviewed
See detailLow molecular weight heparin and central neural blockade
BRICHANT, Jean-François ULg

in BRICHANT, Jean-François (Ed.) Low molecular weight heparin and central neural blockade (1997)

Detailed reference viewed: 8 (1 ULg)
Full Text
Peer Reviewed
See detailLow molecular weight poly (2-dimethylamino ethylmethacrylate) polymers with controlled positioned fluorescent labeling: Synthesis, characterization and in vitro interaction with human endothelial cells.
Flebus, Luca ULg; Lombart, François ULg; Sevrin, Chantal et al

in International journal of pharmaceutics (2015), 478(1), 278-287

Poly (2-dimethylamino ethylmethacrylate) (PDMAEMA) is an attractive non-degradable polymer studied as nonviral vector for gene delivery but it can be also adopted for delivery of other biopharmaceutical ... [more ▼]

Poly (2-dimethylamino ethylmethacrylate) (PDMAEMA) is an attractive non-degradable polymer studied as nonviral vector for gene delivery but it can be also adopted for delivery of other biopharmaceutical drugs. As a parenteral carrier, the PDMAEMA free form (FF) might interact with tissues and cells. Few data are available on its selective internalization and efflux from cells, while the majority of studies published have followed the distribution of DNA complexed with PDMAEMA. In order to address polycation safety, the first aim was to synthesize by atom transfer radical polymerisation (ATRP) fluorescent labeled PDMAEMA of low molecular weight (Mw) (below 15kDa), controlling the position and density of fluorescein. The second goal was to analyze the possible difference in uptake and subcellular distribution of this labeled FF polycation between human umbilical vein endothelial cells (HUVEC) and hCMEC/D3 cells. These two cell lines have been chosen in order to detect selectivity towards the blood-brain barrier (BBB). In both cases, polycation was detected along the plasma membrane followed by progressive migration to the peri-nuclear region, where it overlapped with lysosomal structures. The analysis by fluorescence-activated cell sorting (FACS) of the PDMAEMA uptake by hCMEC/D3 cells showed a significant (p<0.05) inhibition (40%) in presence of 2-dexoxy-d-glucose inhibitor, a result supporting an energy-dependence mechanism(s). Cytotoxicity study showed that low Mw PDMAEMA (10kDa) lead to a minor cytotoxicity compared to the higher ones. As main conclusion this study highlights the similitude in cell trafficking of FF PDMAEMA and data previously reported for PDMAEMA/DNA complexes. [less ▲]

Detailed reference viewed: 45 (9 ULg)
Peer Reviewed
See detailLow noise vacuum-packaged MEMS closed-loop accelerometer using sixth-order multi-feedback loops and local resonator sigma-delta modulators
Chen, F; Yuan, W; Chang, H et al

in Proceedings of "IEEE MEMS Conf. : San Francisco- Janvier 2014" (2014, January)

Detailed reference viewed: 30 (1 ULg)
Full Text
Peer Reviewed
See detailA low rate of trisomy 21 in twin-pregnancies: A cytogenetics retrospective study of 278 cases
Jamar, Mauricette ULg; Lemarchal, C.; Koulischer, Lucien ULg et al

in Genetic Counseling (2003), 14(4), 395-400

Detailed reference viewed: 31 (4 ULg)
Full Text
Peer Reviewed
See detailLow risk in fractures in long-term treatment of Paget’s disease with tiludronate
Audran, M; Combe, B; Michaut, S et al

in Journal of Bone and Mineral Research (1996), 11(S1), 372

Detailed reference viewed: 7 (1 ULg)
Full Text
Peer Reviewed
See detailLow Sickle Cell Disease Mortality In Belgium and Benefit From Hydroxyurea Therapy
Lê, Phu-Quoc; Dedeken, Laurence; Gulbis, Beatrice et al

Poster (2013)

In Western countries, mortality among patients with sickle cell disease (SCD) has decreased in the last decades by means of neonatal screening (NS), infectious prophylaxis and care improvements. The major ... [more ▼]

In Western countries, mortality among patients with sickle cell disease (SCD) has decreased in the last decades by means of neonatal screening (NS), infectious prophylaxis and care improvements. The major causes of death in children include acute chest syndrome, sepsis, splenic sequestration, stroke, aplastic crisis while in adults end-stage organ failure contributes also to premature death. Hydroxyurea (HU) and stem cell transplantation (SCT) are used in Belgium for more than 20 years but their possible influences on survival have not been yet analyzed. The Belgian SCD Registry was created in 2008 including patients of 8 centres. All available data in 2008 were retrospectively encoded in the database. After 2008 and until 2012, all data were recorded prospectively for already registered patients as well as newly diagnosed subjects. Data were registered from NS or from diagnosis (first contact) until last follow up (FU) visit, SCT or death. Data included diagnosis, demography and outcome data. After SCT, only vital status and cause of death were recorded. Up to date, data from 470 pts are recorded (224 males), 412 are HbSS, 14 HbSβ0, 7 HbSβ+ and 37 HbSC. The median age at diagnosis and at last FU was respectively 0.7 year (y) and 9.9 y. The FU for the whole cohort was 3810 patient-years (PY) and with 136 patients aged over 18y, their FU during adulthood accounted for 520 PY. Thirteen patients died (2.8%). The mortality per 100-PY was 0.34 and the median age at death was 14.5 y (range, 1.5-23.7 y). All deaths occurred in HbSS patients, 5 after SCT and 8 due to an acute event. Complete data set is missing for 3 of the 8 patients. For the 5 well documented SCD related deaths, causes were: hemorrhagic stroke (2), sepsis due to S. pneumoniae (1), aplastic crisis (1) and infection during stay in homeland (1). At last FU, 91 patients were transplanted, 182 were on HU, 7 on HU + chronic transfusion (CT), 19 on CT (4 after HU treatment). The remaining 171 patients never had disease modifying therapy (DMT). Compared with the latter, mortality rate for those on HU was significantly reduced (0.1 vs 0.5/100-PY) while patients on HU have longer FU and are older at last FU (Table 1). Among 91 patients transplanted at a median age 6.9 y, 5 died: 3 from acute transplant related toxicity, 1 from secondary acute myeloblastic leukemia after cGVHD, and 1 is unexplained more than 7 years post SCT. The data issued from the most recent NS cohorts report a low death rate during childhood ranging from 0.13 to 0.52. Even if our Belgian cohort is not exclusively issued from neonatal diagnosis, the observed death rate is low (0.34/100-PY). Several methodological biases are present in this partially retrospective study (incomplete or unavailable data, lost of FU, no information if death occurred before the first contact in a center, …). Nevertheless our low mortality is not underestimated since 1) most patients were followed since infancy and during a long period (3810 PY); 2) the FU during adulthood (period of increased mortality) accounted for 520 PY; 3) our cohort represents a very large part of the Belgian SCD population since a national inquiry performed in 2007 estimated the whole SCD population to 500. The effect of HU on mortality has been reported in adults and more recently in children. Despite longer FU and older age at last FU, our data confirms those previously results. With only one case, death by infection is rare while SCT complications contributed to about 40 % of deaths. Even if SCT is the only curative option for SCD, it encompasses a risk of mortality. As life expectancy of SCD patients has been extended which is confirmed by our results (especially for patients on HU), SCT should be reserved for clinically severe cases. Population-based prospective studies evaluating the survival in transplanted and non transplanted patients are needed. [less ▲]

Detailed reference viewed: 21 (1 ULg)
Full Text
Peer Reviewed
See detailLow sodium diet in essential hypertension- Effect on blood cell ions and hemodynamic parameters
Krzesinski, Jean-Marie ULg; Du, Fenghe; Pequeux, Marie-Louise et al

in American Journal of Hypertension : Journal of the American Society of Hypertension (1992), 5

The influence of salt restriction for 3 months on blood pressure, peripheral vascular resistance (observed by occlusive plethysmography), erythrocyte sodium, platelet calcium, and pH, was studied in eight ... [more ▼]

The influence of salt restriction for 3 months on blood pressure, peripheral vascular resistance (observed by occlusive plethysmography), erythrocyte sodium, platelet calcium, and pH, was studied in eight untreated essential hypertensive patients. A low salt diet decreases blood pressure, vascular resistances, erythrocyte sodium, and platelet calcium, but not platelet pH. A strong positive correlation was noted between baseline platelet calcium and vascular resistances (r=0.95, P < .01). But during the salt restriction period, a negative correlation has been observed between the changes in these parameters, which casts doubt on the use of the platelet as a mode of the smooth muscle cell. [less ▲]

Detailed reference viewed: 22 (3 ULg)
Full Text
Peer Reviewed
See detailLow T-cell chimerism is not followed by graft rejection after nonmyeloablative stem cell transplantation (NMSCT) with CD34-selected PBSC.
Baron, Frédéric ULg; Baudoux, Etienne ULg; Frere, Pascale ULg et al

in Bone Marrow Transplantation (2003), 32(8), 829-34

We investigate the feasibility of CD34-selected peripheral blood stem cell (PBSC) transplantation followed by pre-emptive CD8-depleted donor lymphocyte infusions (DLI) after a minimal conditioning regimen ... [more ▼]

We investigate the feasibility of CD34-selected peripheral blood stem cell (PBSC) transplantation followed by pre-emptive CD8-depleted donor lymphocyte infusions (DLI) after a minimal conditioning regimen. Six patients with advanced hematological malignancies ineligible for a conventional myeloablative transplant (n=5) or metastatic renal cell carcinoma (n=1), and with an HLA-identical (n=4) or alternative (n=2) donor were included. The nonmyeloablative conditioning regimen consisted in 2 Gy TBI alone (n=4), 2 Gy TBI and fludarabine (RCC patient, n=1) or cyclophosphamide and fludarabine (patient who had previously received 12 Gy TBI, n=1). Post transplant immunosuppression was carried out with cyclosporin (CyA) and mycophenolate mofetil (MMF). Initial engraftment was achieved in all patients. One out of six patients (17%) experienced grade > or =2 acute GVHD only after abrupt cyclosporin discontinuation and alpha interferon therapy for life-threatening tumor progression. T-cell chimerism was 23% (19-30) on day 28, 32% (10-35) on day 100, 78% (49-95) on day 180 and 99.5% (99-100) on day 365. Three out of four patients who had measurable disease before the transplant experienced a complete response. We conclude that CD34-selected NMSCT followed by CD8-depleted DLI is feasible and preserves engraftment and apparently also the graft-versus-leukemia (GVL) effect. Further studies are needed to confirm this encouraging preliminary report. [less ▲]

Detailed reference viewed: 56 (6 ULg)
Full Text
See detailLow temperature assembly method of microfluidic bio-molecules detection device
Van Loo, Stéphanie ULg; Stoukatch, Serguei ULg; Van Overstraeten-Schlögel, Nancy et al

in Suga, Tadatomo; Takagi, Hideki; Higurashi, Heiji (Eds.) 2012 3rd IEEE International Workshop on Low Temperature Bonding for 3D Integration (LTB-3D 2012) (2012, May 22)

We developed a microfluidic device for the detection of bio-molecules. The active part of the device is a biofunctionalized interdigitated capacitive sensor. The microsystem consists of a sensor on ... [more ▼]

We developed a microfluidic device for the detection of bio-molecules. The active part of the device is a biofunctionalized interdigitated capacitive sensor. The microsystem consists of a sensor on silicon chip, a microfluidic channel formed by photo-patternable resist and a plastic cover. We implemented a low temperature packaging process to assemble the sensor and prevent the biological material from degradation. [less ▲]

Detailed reference viewed: 104 (58 ULg)
Full Text
Peer Reviewed
See detailLow temperature crystallization of yttrium orthoferrite by organic acid-assisted sol-gel synthesis
Stevens, Frédéric ULg; Cloots, Rudi ULg; Poelman, D. et al

in Materials Letters (2014), 114

Yttrium orthoferrite (YFeO3) is a promising material for visible light photocatalytic applications due to its band gap of 2.2-2.6 eV. However, during the synthesis of YFeO3, unwanted composition can be ... [more ▼]

Yttrium orthoferrite (YFeO3) is a promising material for visible light photocatalytic applications due to its band gap of 2.2-2.6 eV. However, during the synthesis of YFeO3, unwanted composition can be obtained and the crystallization requires temperatures as high as 850 C. Powders of YFeO3 were prepared using a sol-gel method with and without organic acids (citric acid, tartaric acid, malonic acid and oxalic acid) used as organic modifiers. The band gap of these powders was measured by diffuse reflection spectroscopy, and the crystallinity and crystalline phase content were characterized by X-ray diffraction. Organic acids allow a higher purity and facilitate crystallization. This work aims to produce YFeO3 powders at the lowest possible temperature. Citric acid was found to be the best additive: it reduces the crystallization temperature below 450 C. This opens new perspectives such as the deposition of crystalline YFeO3 thin films onto conductive glass for water-splitting applications. © 2013 Elsevier B.V. [less ▲]

Detailed reference viewed: 118 (21 ULg)
Full Text
Peer Reviewed
See detailLow Thiamine Diphosphate Levels in Brains of Patients with Frontal Lobe Degeneration of the Non-Alzheimer's Type
Bettendorff, Lucien ULg; Mastrogiacomo, Frank; Wins, Pierre et al

in Journal of Neurochemistry (1997), 69(5), 2005-2010

We compared the thiamine and thiamine phosphate contents in the frontal, temporal, parietal, and occipital cortex of six patients with frontal lobe degeneration of the non-Alzheimer's type (FNAD) or ... [more ▼]

We compared the thiamine and thiamine phosphate contents in the frontal, temporal, parietal, and occipital cortex of six patients with frontal lobe degeneration of the non-Alzheimer's type (FNAD) or frontotemporal dementia with five age-, postmortem delay-, and agonal status-matched control subjects. Our results reveal a 40-50% decrease in thiamine diphosphate (TDP) in the cortex of FNAD patients, whereas thiamine monophosphate was increased 49-119%. TDP synthesizing and hydrolyzing enzymes were unaffected. The activity of citrate synthase, a mitochondrial marker enzyme, was decreased in the frontal cortex of patients with FNAD, but no correlation with TDP content was found. These results suggest that decreased contents of TDP, which is essentially mitochondrial, is a specific feature of FNAD. As TDP is an essential cofactor for oxidative metabolism and neurotransmitter synthesis, and because low thiamine status (compared with other species) is a constant feature in humans, a nearly 50% decrease in cortical TDP content may contribute significantly to the clinical symptoms observed in FNAD. This study also provides a basis for a trial of thiamine, to improve the cognitive status of the patients. [less ▲]

Detailed reference viewed: 21 (1 ULg)
Full Text
Peer Reviewed
See detailLow TSH requirement and goiter in transgenic mice overexpressing IGF-1 and IGF-1R in the thyroid gland
Clément, S.; Refetoff, S.; Robaye, B. et al

in Endocrinology (2001), 142(12), 5131-5139

Through the cAMP signaling pathway, TSH stimulates thyroid follicular cell proliferation, differentiation, and function. Although the autocrine production of IGF-I in the thyroid gland suggests an ... [more ▼]

Through the cAMP signaling pathway, TSH stimulates thyroid follicular cell proliferation, differentiation, and function. Although the autocrine production of IGF-I in the thyroid gland suggests an important physiological function for this factor in these processes, the exact role of the IGF-I/IGF-I receptor system in vivo remains unclear. Although the mitogenic action of TSH requires the presence of IGF-I or insulin in primary culture of dog and human thyroid cells, IGF-I has an effect equal to and independent of the effect of TSH on cell proliferation in rat thyroid cell lines and may even be the main growth regulator in this case. To investigate the in vivo function of the IGF-I/IGF-I receptor system, transgenic mice overexpressing human IGF-I, IGF-I receptor, or both in the thyroid were generated. Adult transgenic mice did not present external signs of thyroid dysfunction, but mice overexpressing both transgenes had significantly increased gland weight and follicular lumen area. A decreased TSH level together with a slightly increased serum T4 concentration and increased thyroidal iodine uptake were also observed, suggesting that IGF-I and IGF-I receptor stimulate thyroid function to some extent in vivo [less ▲]

Detailed reference viewed: 63 (8 ULg)
Full Text
See detailLow viscosity allophanates containing actinically curable groups
Weikard, Jan; Detrembleur, Christophe ULg; Greszta-Franz, Dorota et al

Patent (2011)

The present invention relates to a process for preparing radiation-curing binders containing allophanate groups by reacting at temperatures of !<=130 DEG C. A) one or more compounds containing uretdione ... [more ▼]

The present invention relates to a process for preparing radiation-curing binders containing allophanate groups by reacting at temperatures of !<=130 DEG C. A) one or more compounds containing uretdione groups with B) one or more OH-functional compounds which contain groups which react, with polymerization, with ethylenically unsaturated compounds on exposure to actinic radiation (radiation-curing groups), C) optionally NCO-reactive compounds other than B), in the presence of D) a catalyst containing at least one zinc compound, to form allophanate groups by opening the uretdione ring. [less ▲]

Detailed reference viewed: 25 (4 ULg)
Full Text
See detailLow viscosity allophanates containing actinically curable groups
Detrembleur, Christophe ULg; Mundstock, Holger; Greszta-Franz, Dorota et al

Patent (2006)

The present invention relates to a process for preparing radiation-curing binders containing allophanate groups by reacting at temperatures of .ltoreq.130.degree.C A) one or more compounds containing ... [more ▼]

The present invention relates to a process for preparing radiation-curing binders containing allophanate groups by reacting at temperatures of .ltoreq.130.degree.C A) one or more compounds containing uretdione groups with B) one or more OH-functional compounds which contain groups which react , with polymerization, with ethylenically unsaturated compounds on exposure to actinic radiation (radiation-curing groups), C) optionally NCO-reactive compounds other than B), in the presence of D) a catalyst containing at least one zinc compound, to form allophanate groups by opening the uretdione ring. The present invention also relates to the binders obtained by the process of the invention and to coating compositions containing these binders. [less ▲]

Detailed reference viewed: 11 (6 ULg)
Full Text
See detailLow viscosity allophanates containing actinically curable groups
Weikard, Jan; Detrembleur, Christophe ULg; Grestza-Franz, Dorota et al

Patent (2006)

The present invention relates to a process for preparing radiation-curing binders containing allophanate groups by reacting at temperatures of <=130 DEG C. A) one or more compounds containing uretdione ... [more ▼]

The present invention relates to a process for preparing radiation-curing binders containing allophanate groups by reacting at temperatures of <=130 DEG C. A) one or more compounds containing uretdione groups with B) one or more OH-functional compounds which contain groups which react, with polymerization, with ethylenically unsaturated compounds on exposure to actinic radiation (radiation-curing groups), C) optionally NCO-reactive compounds other than B), in the presence of D) a catalyst containing at least one zinc compound, to form allophanate groups by opening the uretdione ring. The present invention also relates to the binders obtained by the process of the invention and to coating compositions containing these binders. [less ▲]

Detailed reference viewed: 23 (6 ULg)
Full Text
See detailLow viscosity allophanates containing actinically curable groups
Weikard, Jan; Detrembleur, Christophe ULg; Greszta-Franz, Dorota et al

Patent (2011)

The present invention relates to a process for preparing radiation-curing binders containing allophanate groups by reacting at temperatures of !<=130 DEG C. A) one or more compounds containing uretdione ... [more ▼]

The present invention relates to a process for preparing radiation-curing binders containing allophanate groups by reacting at temperatures of !<=130 DEG C. A) one or more compounds containing uretdione groups with B) one or more OH-functional compounds which contain groups which react, with polymerization, with ethylenically unsaturated compounds on exposure to actinic radiation (radiation-curing groups), C) optionally NCO-reactive compounds other than B), in the presence of D) a catalyst containing at least one zinc compound, to form allophanate groups by opening the uretdione ring. The present invention also relates to the binders obtained by the process of the invention and to coating compositions containing these binders. [less ▲]

Detailed reference viewed: 19 (0 ULg)
Full Text
See detailLow viscosity allophanates containing actinically curable groups
Weikard, Jan; Detrembleur, Christophe ULg; Greszta-Frank, Dorota et al

Patent (2006)

PROBLEM TO BE SOLVED: To provide a process for producing a radiation-curing binder containing an allophanate group; and to provide the binder obtained by the process, and a coating composition containing ... [more ▼]

PROBLEM TO BE SOLVED: To provide a process for producing a radiation-curing binder containing an allophanate group; and to provide the binder obtained by the process, and a coating composition containing the binder. ; SOLUTION: The process comprises reacting at a temperature of <=130[deg.]C (A) one or more compounds containing uretdione groups with (B) one or more OH-functional compounds which contain groups which react, with polymerization, with ethylenically unsaturated compounds on exposure to actinic radiation (radiation-curing groups), (C) optionally NCO-reactive compounds other than (B) in the presence of (D) a catalyst containing at least one zinc compound to form allophanate groups by opening the uretdione ring. [less ▲]

Detailed reference viewed: 45 (2 ULg)